Cardiff Oncology Inc (NASDAQ: CRDF) is -20.74% lower on its value in year-to-date trading and has touched a low of $1.44 and a high of $6.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRDF stock was last observed hovering at around $3.29 in the last trading session, with the day’s gains setting it 0.15%.
Currently trading at $3.44, the stock is -17.30% and 0.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing 4.56% at the moment leaves the stock 10.26% off its SMA200. CRDF registered 103.55% gain for a year compared to 6-month gain of 32.31%. The firm has a 50-day simple moving average (SMA 50) of $3.433 and a 200-day simple moving average (SMA200) of $3.1294.
The stock witnessed a 5.20% loss in the last 1 month and extending the period to 3 months gives it a 30.80%, and is -16.30% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.49% over the week and 11.73% over the month.
Cardiff Oncology Inc (CRDF) has around 32 employees, a market worth around $228.83M and $0.69M in sales. Profit margin for the company is -6241.65%. Distance from 52-week low is 138.89% and -46.42% from its 52-week high. The company has generated returns on investments over the last 12 months (-85.38%).
The EPS is expected to shrink by -6.21% this year
111.0 institutions hold shares in Cardiff Oncology Inc (CRDF), with institutional investors hold 28.99% of the company’s shares. The shares outstanding are 66.52M, and float is at 62.53M with Short Float at 15.20%. Institutions hold 27.36% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 2.63 million shares valued at $5.84 million. The investor’s holdings represent 5.883 of the CRDF Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 2.14 million shares valued at $4.74 million to account for 4.7816 of the shares outstanding. The other top investors are ASSENAGON ASSET MANAGEMENT S.A. which holds 1.22 million shares representing 2.7215 and valued at over $2.7 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.0383 of the shares totaling 0.91 million with a market value of $2.02 million.
Cardiff Oncology Inc (CRDF) Insider Activity
The most recent transaction is an insider purchase by Levine James E., the company’s Chief Financial Officer. SEC filings show that Levine James E. bought 2,752 shares of the company’s common stock on Dec 17 ’24 at a price of $5.42 per share for a total of $14905.0. Following the purchase, the insider now owns 65316.0 shares.
Cardiff Oncology Inc disclosed in a document filed with the SEC on Dec 18 ’24 that Levine James E. (Chief Financial Officer) bought a total of 2,400 shares of the company’s common stock. The trade occurred on Dec 18 ’24 and was made at $5.00 per share for $12000.0. Following the transaction, the insider now directly holds 67716.0 shares of the CRDF stock.
Still, SEC filings show that on Dec 16 ’24, Levine James E. (Chief Financial Officer) acquired 2,564 shares at an average price of $3.83 for $9820.0. The insider now directly holds 62,564 shares of Cardiff Oncology Inc (CRDF).
